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 ABSTRACT 
 
Objective: The objective of this selective EBM review is to determine whether sublingual 
buprenorphine treatment is effective and efficient when compared to traditional neonatal opium 
solution (morphine) in treating newborns with neonatal abstinence syndrome (NAS). 
 
Study Design: Review of one randomized active-control clinical trial, one randomized double-
blind, double-dummy clinical trial, and one retrospective cohort analysis. 
 
Data Sources: All articles were published in English between the years of 2011 and 2017. 
Articles were obtained from peer-reviewed journals and databases using PubMed and Embase.  
 
Outcomes: Outcomes measured were length of stay using the neonates birth date and hospital 
discharge date as well as duration of treatment using the cessation date of treatment once 
MOTHER NAS score <8.  
 
Results: Kraft et al. (2011) found a statistically significant decrease in hospital stay and duration 
of treatment with buprenorphine when compared to morphine treatment of NAS. Further study 
by Kraft et al. (2017) again found a statistically significant decrease in hospital stay and duration 
of treatment with buprenorphine compared to morphine. Hall et al. (2016) found in their 
retrospective cohort study that patients treated with buprenorphine had a shorter hospital stay and 
a shorter duration of treatment when compared to patients who were treated with morphine or 
methadone.  
 
Conclusions: All three studies confirm that buprenorphine treatment is both effective and 
efficient when compared to traditional neonatal opium solution (morphine) in treating newborns 
with neonatal abstinence syndrome. Further studies should place focus on treatment weaning the 
mother from the offending substance and its effect on the incidence of NAS, length of stay in the 
hospital, and possible elimination of pharmacologic intervention in neonates.  
 
Keywords: neonatal abstinence syndrome, sublingual buprenorphine 
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INTRODUCTION 
Neonatal abstinence syndrome (NAS) occurs in newborns who were exposed to drugs in 
utero and results in the presence of signs and symptoms of withdrawal. Presentation of NAS 
includes tremors, irritability, high-pitched crying, increased muscle tone, vomiting, poor sleep, 
diarrhea, tachypnea, sweating and low-grade fever. In addition to withdrawal, the newborns are 
also at risk for poor intrauterine growth, premature birth, seizures, and birth defects. It is evident 
that this is an unfortunate series of events and difficult way to begin life.  
The current opioid crisis that has plagues adults in the US today has sadly affected the 
neonate population as well. The incidence of NAS has significantly risen over the last 10 years, 
with the number of neonates admitted to the NICU with NAS increasing 10-fold from 2005 to 
2011.1 In 2009, NAS averaged $53,400 in hospital charges with an associated average hospital 
stay of 16.4 days, whereas, uncomplicated births average $9,500 and 3.3 days in the hospital.2 A 
recorded 9,674 neonates were kept in the hospital after birth for NAS in 2009.3  
This influx in neonatal patients has put an extensive amount of stress on the 
neonatologist’s workload. The high demand for specialized physicians, and the subsequent low 
supply has provided a window of opportunity for physician assistants.4 With some additional 
training, PAs can serve a vital role in the care of critically ill neonates and their families.4 They 
have the ability to review labs, intubate neonates, accompany critical patients to procedures, 
initiate treatment, and provide an integral role in providing direction and communication in 
patient care.5 
The exact pathophysiologic mechanism of opioid withdrawal in an infant is unknown. 
However, it is known that the low molecular weight water-soluble opioids, as well as the 
synthetic opiates, are easily able to cross the placenta and effect the fetus.1 The locus coeruleus 
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of the pons is the most important and sensitive center in opioid withdrawal. Lack of opioids is 
sensed, and an increased production of norepinephrine occurs, which causes many of the signs of 
NAS.1  
Treatment for NAS includes non-pharmacologic as well as pharmacologic regimens. 
Non-pharmacologic therapies include swaddling, frequent feeds, pacifiers, music, and massage 
therapy. Pharmacologic treatments consist of morphine, methadone, phenobarbital, clonidine, 
and buprenorphine. Most treatment options for opioid withdrawal, as listed above, are for use in 
adults. The standard of care for NAS has been morphine, but it has its own side effects and a 
longer treatment duration. Buprenorphine has been routinely used in adults for abstinence 
therapy and symptom control with lower rates of respiratory depression. This finding comes as a 
highly attractive treatment option for neonates since NAS already puts a significant amount of 
stress on the newborn.  
OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not sublingual 
buprenorphine treatment is effective and efficient when compared to traditional neonatal opium 
solution (morphine) in treating newborns with neonatal abstinence syndrome (NAS). 
METHODS 
 Two randomized control trials and one retrospective cohort analysis were selected for this 
review. The population included newborns with neonatal abstinence syndrome with intervention 
consisting of sublingual buprenorphine treatment. All three studies had a treatment group using 
buprenorphine and an experimental group who received neonatal opium solution (morphine). 
Outcomes measured were the efficacy of buprenorphine as measured by the duration of 
treatment and the efficiency as measured by the length of stay in the hospital.  
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 Databases used to select adequate studies include PubMed and Embase. Keywords used 
during the search were “neonatal abstinence syndrome” and “buprenorphine”. The three chosen 
studies were written in English and published between the years 2011-2017. Inclusion criteria for 
all three articles included randomized control trials and retrospective cohort analyses. Exclusion 
criteria, which all studies abided by, included studies that contained neonates without NAS and 
used methadone as the experimental therapy treatment. Table 1 displays detailed individual study 
components as well as inclusion and exclusion criteria. Statistical analysis of data included the 
mean change from baseline, median, confidence intervals, and p-values.  
OUTCOMES MEASURED 
 This meta-review dissects the difference in length of stay in the hospital and the duration 
of treatment when comparing buprenorphine and morphine as treatment options. Length of stay 
was determined by the neonate’s discharge date compared to their birth date. Duration of 
treatment was determined using the MOTHER NAS score. The MOTHER NAS score is a 
variation of the Finnegan scoring instrument.6 The score ranges from 0 to 42, with the higher end 
signifying a greater severity (Table 2).6 Cessation of treatment in patients was determined by a 
MOTHER score of <8. 
RESULTS 
 Kraft et al. (2011) ran a randomized, open-label, active-control clinical trial comparing 
the standardized oral morphine to the experimental sublingual buprenorphine on 24 term infants 
with NAS in need of pharmacologic treatment.3 Treatment was initiated in any full-term neonate 
(≥37 weeks’ gestation) with a total MOTHER NAS score ≥24 after three consecutive counts, or a 
single score of ≥12.3 Additional inclusion and exclusion criteria is indicated in Table 1. 
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Table 1 – Demographics & Characteristics of Included Studies 
Study Type # 
Pts 
Age Inclusion Criteria Exclusion Criteria W/D Interventions 
Kraft3 
(2011) 
Active-
control RCT 
24 > 37 
weeks 
gestation 
Infants with in 
utero exposure to 
opioids, requiring 
pharmacologic 
treatment for 
NAS 
Exposure to 
benzodiazepines, 
maternal use of 
alcohol, medical 
illness, major 
congenital 
malformations, or 
breastfed infants. 
0 Sublingual 
buprenorphine 
15.9 mcg/kg in 
3 doses; 
Morphine 0.4 
mg/kg/d in 6 
doses; adjunct 
Phenobarbital 
therapy when 
max dose of 
Buprenorphine 
(60 mcg/kg/d) 
or Morphine (1 
mg/kg/d) is 
reached and 
NAS not 
controlled 
Kraft6 
(2017) 
Double-
blind, 
double-
dummy RCT 
63 > 37 
weeks 
gestation 
Term infants 
exposed to 
opioids in utero 
with signs of 
NAS. 
Major congenital 
malformations, 
birth weight of 
<2200g, a 
medical/neurologic 
illness, 
hypoglycemia 
requiring IV 
glucose, bilirubin 
level >20 mg/dL, 
maternal use of a 
benzodiazepine 30 
days before birth, 
or seizures. 
Breastfeeding 
exclusion criteria 
amended during 
study. 
5 Sublingual 
buprenorphine 
15.9 mcg/kg in 
3 doses; 
Morphine 0.4 
mg/kg/d in 6 
doses; 
Phenobarbital 
rescue dose 
when max dose 
of 
Buprenorphine 
(60 mcg/kg/d) 
or Morphine (1 
mg/kg/d) is 
reached and 
NAS not 
controlled 
Hall7 
(2016) 
Retrospective 
Cohort 
Analysis 
360 >34 
weeks 
gestation 
Infants treated 
pharmacologically 
for NAS with an 
opioid during the 
4-year period. 
No infant had a 
major congenital 
malformation or 
experienced 
iatrogenic 
withdrawal. 
0 Buprenorphine, 
Methadone, 
Methadone, 
adjunct 
phenobarbital 
therapy. 
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Table 2 – MOTHER NAS Scale; Scored Elements6 
Signs and Symptoms Score 
Crying: Excessive high pitched 
Crying: Continuous high pitched 
2 
3 
Sleeps <1 hour after feeding 
Sleeps <2 hours after feeding 
Sleeps <3 hours after feeding 
3 
2 
1 
Hyperactive Moro Reflex 
Markedly Hyperactive Moro Reflex 
1 
2 
Mild Tremors: Disturbed 
Moderate-Severe Tremors: Undisturbed 
1 
2 
Increased Muscle Tone 1-2 
Excoriation 1-2 
Generalized seizure (or convulsion) 8 
Fever >37.3 C (99.2 F) 1 
Sweating  1 
Nasal Stuffiness 1 
Frequent Yawning (≥4 successive times) 1 
Sneezing (≥4 successive times) 1 
Tachypnea (Respiratory Rate >60/min) 2 
Poor feeding 2 
Vomiting (or regurgitation) 2 
Loose Stools  2 
Failure to thrive (Current weight > 10% 
below birth weight 90%) (record daily 
weights) 
2 
Excessive irritability  1-3 
 
Patients were randomized to traditional treatment of oral morphine and an experimental group of 
sublingual buprenorphine with 12 participants in each group.3 This study adopted an intention-
to-treat basis.3 Using their continuous data, they determined that buprenorphine treatment had 
statistically significant improvements in both duration of treatment and length of hospital stay 
(Table 3).  
Table 3 – Outcomes of Buprenorphine and Morphine 
Outcome Buprenorphine (Mean ± SD) Morphine (Mean ± SD) P-value 
Length of Stay  32 ± 24 42 ± 13 0.05 
Duration of Treatment  23 ± 12 38 ± 14 0.01 
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 Expanding on their prior research, Kraft et al. (2017) took it upon themselves to perform 
Wish a double-blind, double-dummy clinical trial.1 In this study, they had 63 full-term infants 
(≥37 weeks’ gestation) randomly assigned to receive either sublingual buprenorphine or oral 
morphine to treat their NAS.6 As with their previous study they used the same MOTHER NAS 
score guidelines, three consecutive scores totaling ≥24 or one single score ≥12.6 Table 1 contains 
additional inclusion and exclusion criteria for the study. Throughout their research, they lost 5 
participants, 3 from the buprenorphine group and 2 from the morphine group, all who were 
withdrawn by their parents due to concern for ineffective treatment.6 The 5 withdrawn patients 
received open-label morphine due to the researchers following the intention-to-treat principle.6 
Again the researchers further proved, with more reliable study design, that buprenorphine 
therapy had a statistically significant improvement in shortening the duration of treatment and 
the length of hospital stay (Table 4).  
Table 4 - Outcomes of Buprenorphine and Morphine with P-value and 95% CI 
Outcome Buprenorphine 
(median); N=33 
Morphine 
(median); N=30 
P-value Difference 
(95% CI) 
Length of Stay 21 (7 to 71) 33 (18 to 70) <0.001 -12 (-22 to -7) 
Duration of 
Treatment 
15 (3 to 67) 28 (13 to 67) <0.001 -13 (-21 to -7) 
 
 In a retrospective cohort analysis Hall et al. (2016) evaluated 360 infants treated for 
neonatal abstinence syndrome over a four-year period.7 In June 2015, a standardized weaning 
protocol was put in place with sublingual buprenorphine as standard treatment despite the type of 
intrauterine opioid exposure.7 Detailed inclusion and exclusion criteria are shown in Table 1. 
Overall, the study determined that neonates treated with buprenorphine treatment had a 3.0-day 
reduction in treatment duration and a 2.8-day reduction in hospital stay (Table 5).7 Additionally, 
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they were able to determine that buprenorphine treatment resulted in hospital discharge of infants 
without need for adjunct therapy (p <0.001).7 
Table 5 – Retrospective Analysis of Outcomes for Treatment with Buprenorphine vs. Morphine 
Regardless of Intrauterine Exposure  
Outcome Buprenorphine,  
Mean (95% CI); N=174 
Morphine, 
Mean (95% CI); N=186 
P-value 
Length of Stay  12.4 (11.3-13.6) 15.2 (14.1-16.4) <0.001 
Duration of Treatment  7.4 (6.3-8.5) 10.4 (9.3-11.5) <0.001 
 
DISCUSSION 
 The beginning of life for a neonate is stressful in the physiological sense. They have gone 
from a protective, life-sustaining, and nutrient providing uterine environment to the open world. 
Adding on additional stress from opioid withdrawal is the last thing a neonate needs to 
overcome. That being said, all three of the studies in this evidence-based systematic review 
demonstrate that treatment with buprenorphine allows for a shorter hospital stay and less time in 
treatment. While buprenorphine has been proven effective, it comes with its short-comings.  
 In both Kraft et al. (2011, 2017) studies, it was noted that a few patients receiving 
buprenorphine required supplemental treatment with phenobarbital to provide adequate disease 
stability.3,6 It is unclear if the need for phenobarbital necessarily indicates treatment failure in the 
infant population.3 Many factors go into neonatal withdrawal such as the type of abused agent 
used, strength and quantity of offending agent, and duration of intrauterine exposure.8 With this 
in mind, it is no question that an infant may require supplemental treatment for symptom control.  
 Another item to consider is the type of intrauterine drug exposure included in the study. 
One might challenge the fact that both Kraft et al. (2011, 2017) studies excluded the use of 
benzodiazepines (Table 1). However, it should be noted that the Hall et al. (2016) retrospective 
study did not have any exclusion criteria for the offending agents and had the same significant 
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results for both measured outcomes (Table 5). This finding should further suggest that even 
when the type of intrauterine exposure was not controlled for, the outcome still presented 
buprenorphine as the better treatment option. 
 Limitations to this particular systemic review include the fact that two of the chosen 
studies were conducted by the same research group at the same hospital in Philadelphia, PA. It is 
known that the second study expanded on the limitations that they discovered in their first study, 
such as the number of participants and study control factors.3 After improving their parameters 
and expanding their study size, they were still able to identify a positive outcome with 
buprenorphine over morphine treatment.6 This duplication in research teams was recognized 
during the study selection process and an attempt was made to further support the systematic 
review by selecting a study from a different location, such as with Hall et al. (2016). In doing 
this, however, the strength of a randomized control trial was sacrificed and thus replaced with a 
retrospective cohort analysis.  
CONCLUSION 
 This systemic review confirms that buprenorphine treatment is both effective and 
efficient when compared to traditional neonatal opium solution (morphine) in treating newborns 
with neonatal abstinence syndrome.  Since the United States is undergoing such an epidemic 
with opioid abuse and addiction in the adult population, it is important not to forget about others 
that may subsequently suffer the consequence. These findings come at a crucial time for 
neonates born to mothers who battle with addiction. Further studies should be recommended in 
researching the safest amount of buprenorphine that a neonate can receive to try to limit or 
eliminate the need for supplemental phenobarbital. Additionally, it might be beneficial to focus 
on the mother and her access to adequate care both for prenatal and behavioral management. 
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Perhaps a study could explore the effectiveness of weaning a mother off the offending agents 
early in gestation and the resulting incidence in NAS, length of hospital stay, or if it omits a need 
for pharmacologic treatment altogether. 
 REFERENCES 
 
1. Prabhakar Kocherlakota. Neonatal abstinence syndrome. Pediatrics. 
2014;134(2):e547. https://search.proquest.com/docview/1552145460.  
 
2. Patrick SW, Schumacher RE, Benneyworth BD, Krans EE, McAllister JM, Davis MM. 
Neonatal abstinence syndrome and associated health care expenditures: United states, 
2000-2009. JAMA. 2012;307(18):1934-1940. http://dx.doi.org/10.1001/jama.2012.3951. 
doi: 10.1001/jama.2012.3951.  
 
3. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose 
schema of sublingual buprenorphine in the treatment of the neonatal opioid abstinence 
syndrome. Addiction. 2011;106(3):574-
580. http://onlinelibrary.wiley.com.ezproxy.pcom.edu:2048/doi/10.1111/j.1360-
0443.2010.03170.x/abstract. doi: 10.1111/j.1360-0443.2010.03170.x.  
 
4. Perman S. A day in the life. JAAPA: Official Journal of the American Academy of 
Physician Assistants. 2009;22(8):15-16. 
https://www.ncbi.nlm.nih.gov/pubmed/19725408. doi: 10.1097/01720610-200908000-
00005.  
5. Eric W Reynolds, J Timothy Bricker. Nonphysician clinicians in the neonatal intensive 
care unit: Meeting the needs of our smallest patients. Pediatrics. 2007;119(2):361-369. 
doi: 10.1542/peds.2006-1084.  
6. Kraft WK, Adeniyi-Jones S, Chervoneva I, et al. Buprenorphine for the treatment of the 
neonatal abstinence syndrome. N Engl J Med. 2017;376(24):2341-
2348. http://dx.doi.org.ezproxy.pcom.edu:2048/10.1056/NEJMoa1614835. doi: 
10.1056/NEJMoa1614835.  
 
7. Hall ES, Isemann BT, Wexelblatt SL, et al. A cohort comparison of buprenorphine versus 
methadone treatment for Neonatal abstinence syndrome. The Journal of Pediatrics. 
2016;170:44.e1. http://www.sciencedirect.com.ezproxy.pcom.edu:2048/science/article/pii
/S0022347615014511. doi: //doi-org.ezproxy.pcom.edu/10.1016/j.jpeds.2015.11.039.  
 
8. Neonatal abstinence syndrome. Stanford Children's Health 
Website. https://www.stanfordchildrens.org/en/topic/default?id=neonatal-abstinence-
syndrome-90-P02387. Accessed 11/29/2018.  
 
 
